 On Thursday, 492021, KemPharm announced an updated commercialization agreement with its marketing partner, Corium. This was based on a post-approval commercial assessment conducted with GPC, Coriums parent. The agreement added increased royalty rates, and 130M in potential sales milestones, with an increase of 7m in regulatory milestones. Total sales and regulatory milestones stand at 590m. 